Peter Willis on Muck Rack

Peter Willis

Verified
  • Freelance Journalist and Contributing Editor, Classic Boat
Guildford
As seen in: Classic Boat, The Daily Mirror, WhatCulture, Daily Maverick, Lexology, Kirkus Reviews, Mondaq, Concurrences, Bird & Bird Podcasts
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Peter

Contact Peter, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

The Future of Competition Law Enforcement in the UK Panel Event – Key Takeaways

|
By Peter Willis , Emma Radcliffe, Saskia King
| Bird & Bird Podcasts
Bird & Bird's London competition team recently hosted a panel event on the future of competition law enforcement in the UK on 23 April 2026, bringing together in-house counsel, economists and representatives from the Competition and Markets Authority (“CMA”) and Ireland's Competition and Consumer Protection Commission (“CCPC”).
Open in Who Shared Issue with article?

Competitive Edge Newsletter: Competition Law - January 2026

|
By Peter Willis , Flora McCarthy
| Bird & Bird Podcasts
Home Insights Competitive Edge Newsletter: Competition Law - January 2026 Keeping you up to date on Competition and EU law developments in Europe and beyond.
Open in Who Shared Issue with article?

The England & Wales Court of Appeal upholds the Competition Authority’s £99M fine for charging the NHS excessively high prices for a thyroid drug (Advanz) - Concurrences

|
By Peter Willis , Dina Kallay, Emmanuel Combe, Flora McCarthy
| Concurrences
Estimated reading time: 4 min Introduction In a significant ruling for competition law enforcement in the pharmaceutical sector, the Court of Appeal has unanimously upheld the Competition and Markets Authority’s (CMA) decision that Advanz abused its dominant position by charging excessive and unfair prices for liothyronine tablets to the NHS.
Open in Who Shared Issue with article?
See all 17 licensed articles (21 Total)

Actions

Share this page

Get in touch with Peter

Contact Peter, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified